NCT00895479View on ClinicalTrials.gov

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence

PHASE3TerminatedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
End Stage Renal Disease
Interventions
PROCEDURE

Graft placement surgery plus Trinam therapy

"Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.~Control arm: graft placement surgery"

Trial Locations (12)

CA 90822

Long Beach VA Healthcare System, Long Beach

KY 42003

Four Rivers Clinical Research Inc, Paducah

LA 70809

Baton Rouge General Hospital, Baton Rouge

LA 71103

Louisiana State University Health Sciences Center, Shreveport

MO 63110

Washington University School of Medicine, St Louis

NY 10029

Mount Sinai Medical Center, New York

NY10025

St Luke's Roosevelt Hospital, New York

NC 27710

Duke University Medical Center, Durham

OH 45267

University of Cincinnati, Cincinnati

OH 43210

Ohio State University Division of Nephrology, Columbus

TX 79415

Texas Tech University Medical Center, Lubbock

WA 98104

Harborview Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Ark Therapeutics Ltd

INDUSTRY

NCT00895479 - Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence | Biotech Hunter | Biotech Hunter